Mary C. Fulbright

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.
  2025 L1 73/100

1 assessed by us (0 reproduced) · 28 not yet assessed — every PubMed paper on record, linked below.

• Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms ↗

  Blood · 2026 · PMID 42345360
  not yet assessed
• RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia

  Nature Communications · 2025 · PMID 39820365
  L1 73/100
• A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies ↗

  Cell Communication and Signaling · 2025 · PMID 41402890
  not yet assessed
• Activating STIM1 mutations drive the development of myelofibrosis ↗

  Blood · 2025
  not yet assessed
• In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms ↗

  Blood · 2024 · PMID 38457657
  not yet assessed
• Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms ↗

  Experimental Hematology · 2024 · PMID 38340948
  not yet assessed
• Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1 ↗

  Blood · 2024
  not yet assessed
• Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis ↗

  Blood · 2024
  not yet assessed
• Construction of a Myeloid Gene Signature Revealing Novel Therapeutic Targets for Myeloid Malignancies ↗

  Blood · 2024
  not yet assessed
• Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms ↗

  Journal of Clinical Investigation · 2023 · PMID 38060311
  not yet assessed
• Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice ↗

  Experimental Hematology · 2023 · PMID 37611729
  not yet assessed
• RSK1 Is an Exploitable Dependency in Myeloid Malignancies ↗

  Blood · 2023
  not yet assessed
• In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms ↗

  Blood · 2023
  not yet assessed
• Galectin-1 Fuels Monocyte-Driven Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms ↗

  Blood · 2023
  not yet assessed
• Aberrant Activity of the Calcium Sensor STIM1 Underlies Congenital Platelet Disorders and Myeloproliferative Neoplasms ↗

  Blood · 2023
  not yet assessed
• DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression ↗

  Nature Cancer · 2022 · PMID 36581736
  not yet assessed
• Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib ↗

  British Journal of Haematology · 2022 · PMID 35128632
  not yet assessed
• Multiomic Profiling Reveals Metabolic Alterations Mediating Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2022
  not yet assessed
• Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms ↗

  Blood · 2022
  not yet assessed
• Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition ↗

  Blood Advances · 2021 · PMID 34644371
  not yet assessed
• Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib ↗

  Blood · 2018
  not yet assessed
• Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia ↗

  Leukemia · 2016 · PMID 28008177
  not yet assessed
• SpDamID: Marking DNA Bound by Protein Complexes Identifies Notch-Dimer Responsive Enhancers ↗

  Molecular Cell · 2016
  not yet assessed
• Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia ↗

  Blood · 2016
  not yet assessed
• SpDamID: Marking DNA Bound by Protein Complexes Identifies Notch-Dimer Responsive Enhancers ↗

  Molecular Cell · 2015 · PMID 26257285
  not yet assessed
• NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia ↗

  Blood · 2015
  not yet assessed
• Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms ↗

  Blood · 2014
  not yet assessed
• Real-Time Imaging of Notch Activation with a Luciferase Complementation-Based Reporter ↗

  Science Signaling · 2011 · PMID 21775282
  not yet assessed
• Host homes: one alternative for troubled youths. ↗

  PubMed · 1989 · PMID 3208552
  not yet assessed